Research programme: therapeutics for bone disorders therapeutics - Scil Technology

Drug Profile

Research programme: therapeutics for bone disorders therapeutics - Scil Technology

Alternative Names: Research programme: orthopaedic therpaeutics - Scil Technology; ST 01

Latest Information Update: 31 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scil Technology
  • Class Bone morphogenetic proteins
  • Mechanism of Action Intercellular signalling peptide and protein stimulants; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bone disorders

Most Recent Events

  • 31 Mar 2011 Preclinical development is ongoing in Germany
  • 25 May 2005 Compounds in this programme are available for licensing (http://www.scil.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top